Key Drivers
- Strong liquidity
- Severe losses
- High cash burn
AIAI Summary
Prothena's investment case has shifted to a partner-enabled, capital-light model where its cash-rich balance sheet and near-term milestone receipts create asymmetric upside if collaborators (e.g., Novo, BMS) hit enrollment/readout triggers, but investors should treat the stock as event-driven and size positions to protect the cash-valued downside given binary partner execution and timing risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Severe losses
- •High cash burn
PRTA is cash-rich and virtually debt-free but suffers deep operating losses, negative free cash flow, and high cash burn that threaten its runway without material revenue growth or cost cuts.
Price Behavior
Key Price Behavior Insights:
- •Above SMA
- •Near-term resistance
- •Strong support cluster
Over the last month the stock has rallied ~12.8% to $10.50 and sits well above the last month SMA (~$9.49), signaling short-term bullish momentum but facing near-term resistance around $10.65.
Swing from $8.54 to $10.65 (~22–25%) over last month shows elevated volatility
Sentiment & News
Key News Insights:
- •Analyst upside
- •Estimate revisions
- •Clinical updates
Prothena drew strong analyst optimism (aggregate price‑target implying ~120% upside) even as that metric's reliability was questioned, while presenting prasinezumab and BMS‑986446 updates at AD/PD, signaling market enthusiasm paired with active pipeline progress.
Elevated analyst sentiment could boost near‑term share momentum and partnering interest, but upcoming clinical readouts will determine sustainable value
Similar Companies in Healthcare
Other companies in the same sector with AI ratings